Chimeric Therapeutics Ltd (CHM) - Net Assets
Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has net assets worth AU$1.97 Million AUD (≈ $1.40 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$21.57 Million ≈ $15.26 Million USD) and total liabilities (AU$19.60 Million ≈ $13.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Chimeric Therapeutics Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$1.97 Million |
| % of Total Assets | 9.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -92.14% |
| 10-Year Change | N/A |
| Growth Volatility | 31.15 |
Chimeric Therapeutics Ltd - Net Assets Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore CHM total asset value for the complete picture of this company's asset base.
Annual Net Assets for Chimeric Therapeutics Ltd (2020–2025)
The table below shows the annual net assets of Chimeric Therapeutics Ltd from 2020 to 2025. For live valuation and market cap data, see Chimeric Therapeutics Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.97 Million ≈ $1.40 Million |
-20.06% |
| 2024-06-30 | AU$2.47 Million ≈ $1.75 Million |
-56.36% |
| 2023-06-30 | AU$5.66 Million ≈ $4.01 Million |
-77.98% |
| 2022-06-30 | AU$25.71 Million ≈ $18.19 Million |
+2.29% |
| 2021-06-30 | AU$25.13 Million ≈ $17.78 Million |
+39423.84% |
| 2020-06-30 | AU$-63.91K ≈ $-45.22K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chimeric Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7626999300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$70.16 Million | 3553.39% |
| Other Comprehensive Income | AU$8.15 Million | 412.58% |
| Total Equity | AU$1.97 Million | 100.00% |
Chimeric Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Chimeric Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turbon AG
F:TUR
|
$8.84 Million |
|
Zeta Network Group
NASDAQ:ZNB
|
$8.84 Million |
|
Vanadium Resources Ltd
AU:VR8
|
$8.84 Million |
|
Semacom Integrated Tbk PT
JK:SEMA
|
$8.84 Million |
|
Touchwood Entertainment Limited
NSE:TOUCHWOOD
|
$8.84 Million |
|
Ease2pay NV
AS:EAS2P
|
$8.83 Million |
|
Urban Logistics Reit PLC
LSE:SHED
|
$8.83 Million |
|
Domino’s Pizza Group PLC
LSE:DOM
|
$8.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chimeric Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,470,068 to 1,974,514, a change of -495,554 (-20.1%).
- Net loss of 10,430,424 reduced equity.
- Share repurchases of 572,009 reduced equity.
- New share issuances of 8,204,420 increased equity.
- Other comprehensive income increased equity by 2,627,509.
- Other factors decreased equity by 325,050.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-10.43 Million | -528.25% |
| Share Repurchases | AU$572.01K | -28.97% |
| Share Issuances | AU$8.20 Million | +415.52% |
| Other Comprehensive Income | AU$2.63 Million | +133.07% |
| Other Changes | AU$-325.05K | -16.46% |
| Total Change | AU$- | -20.06% |
Book Value vs Market Value Analysis
This analysis compares Chimeric Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 106.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | AU$0.00 | AU$0.16 | x |
| 2021-06-30 | AU$0.08 | AU$0.16 | x |
| 2022-06-30 | AU$0.07 | AU$0.16 | x |
| 2023-06-30 | AU$0.01 | AU$0.16 | x |
| 2024-06-30 | AU$0.00 | AU$0.16 | x |
| 2025-06-30 | AU$0.00 | AU$0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chimeric Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -528.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -262.83%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 10.92x
- Recent ROE (-528.25%) is below the historical average (-269.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-57.62K |
| 2021 | -60.14% | -571190.89% | 0.00x | 1.45x | AU$-17.63 Million |
| 2022 | -61.85% | -607.48% | 0.08x | 1.36x | AU$-18.47 Million |
| 2023 | -457.84% | -575.20% | 0.20x | 3.95x | AU$-26.48 Million |
| 2024 | -507.27% | -168.01% | 0.49x | 6.18x | AU$-12.78 Million |
| 2025 | -528.25% | -262.83% | 0.18x | 10.92x | AU$-10.63 Million |
Industry Comparison
This section compares Chimeric Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,810,720
- Average return on equity (ROE) among peers: -71.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chimeric Therapeutics Ltd (CHM) | AU$1.97 Million | 0.00% | 9.92x | $8.84 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more